CONTROLLED TRIAL OF DEXAMETHASONE THERAPY IN INFANTS WITH BRONCHOPULMONARY DYSPLASIA
References (27)
- et al.
Changing incidence of bronchopulmonary dysplasia
J Pediatr
(1979) - et al.
Bronchopulmonary dysplasia: The need for epidemiologic studies
J Pediatr
(1979) Epidemiology of bronchopulmonary dysplasia
J Pediatr
(1979)Observations on bronchopulmonary dysplasia
J Pediatr
(1979)- et al.
Corticosteroids inhibit prostaglandin release from profused lungs of sensitized guinea pig
Prostaglandins
(1975) - et al.
Infants with bronchopulmonary dysplasia: Growth pattern and neurologic and developmental outcome
Am J Dis Child
(1982) Chronic complications of respiratory therapy in the newborn
- et al.
Fat embolism: The effect of corticosteroids on experimental fat embolism in the rat
Surgery
(1968) - et al.
Influence of corticosteroid on recovery from oxygen toxicity
Am Rev Respir Dis
(1974) - et al.
Corticosteroid treatment of 14 newborns with bronchopulmonary dysplasia
Clin Res
(1979)
Treatment of neonatal bronchopulmonary dysplasia with steroids
Ped Res
Corticosteroid responsiveness in chronic lung disease of prematurity
Ped Res
Treatment of severe neonatal bronchopulmonary dysplasia with dexamethasone
Ped Res
Cited by (242)
Postnatal Cytomegalovirus Infection Among Preterm Infants
2023, Principles of NeonatologyContributions of the NICHD neonatal research network to the diagnosis, prevention, and treatment of bronchopulmonary dysplasia
2022, Seminars in PerinatologyCitation Excerpt :During the past 35 years, randomized trials and observational studies conducted by the NRN have contributed to our current understanding of the benefits and harms of various corticosteroid medications and dosing strategies used to prevent BPD. Following publication of several small trials conducted in the 1980s showing short-term respiratory benefit with prolonged, high-dose courses of dexamethasone (0.5mg/kg/day starting dose, treatment duration up to 42 days), the NRN conducted two trials in the 1990s that evaluated different dexamethasone treatment regimens.38–42 The first, published in 1998, compared 14-day courses of dexamethasone (0.5mg/kg/day starting dose) initiated at either 2 weeks or 4 weeks of age in 371 ventilator-dependent infants born with birth weights <1500g.41
BPD treatments: The never-ending smorgasbord
2021, Seminars in Fetal and Neonatal MedicineCitation Excerpt :Because inflammation plays an important part in the pathogenesis of BPD, it was hoped that corticosteroids administered postnatally might reduce lung injury and BPD. Following evidence of effectiveness from several small trials in the 1980's [33,34], postnatal corticosteroids (PCS) became widely used in neonatal units despite the absence of long-term safety data, and animal studies which suggested adverse effects on brain development [35,36]. Subsequent follow-up data confirmed an increased risk of neurological impairment [37,38], and during the 2000's a substantial reduction in PCS use followed.
Corticosteroids for Neonatal Hypotension
2020, Clinics in Perinatology